Skip to content
Loncastuximab
Zynlonta (loncastuximab) is an antibody pharmaceutical. Loncastuximab was first approved as Zynlonta on 2022-12-20. It has been approved in Europe to treat b-cell lymphoma and large b-cell lymphoma diffuse. It is known to target B-lymphocyte antigen CD19.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
zynlontaBiologic Licensing Application2022-10-19
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
C9084
Injection, loncastuximab tesirine-lpyl, 0.1 mg
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403C83.3661—113
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Follicular lymphomaD008224C8224———6
Mantle-cell lymphomaD020522C83.133———5
Non-hodgkin lymphomaD008228C85.931———4
B-cell lymphomaD01639322———4
LymphomaD008223C85.911———2
B-cell chronic lymphocytic leukemiaD015451C91.111———2
Waldenstrom macroglobulinemiaD008258C88.011———2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Burkitt lymphomaD002051C83.72————2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLONCASTUXIMAB
INNloncastuximab
Description
Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1879918-31-6
RxCUI—
ChEMBL IDCHEMBL4297238
ChEBI ID—
PubChem CID—
DrugBankDB16222
UNII IDNYM5HO7I39 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CD19
CD19
Organism
Homo sapiens
Gene name
CD19
Gene synonyms
NCBI Gene ID
930
Protein name
B-lymphocyte antigen CD19
Protein synonyms
B-lymphocyte surface antigen B4, CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12
Uniprot ID
P15391
Mouse ortholog
Cd19 (12478)
B-lymphocyte antigen CD19 (Q542B2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 250 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details